SEC Filing Analysis: REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)

Executive Summary

• Trading Significance: Low
• Key Takeaway: A director received a routine, compensatory grant of 8,200 stock options with a $0 transaction value.
• Market Impact: Neutral. This is a standard compensation event and not indicative of a change in insider sentiment.

Company Information

Field	Value
Company	REVIVA PHARMACEUTICALS HOLDINGS, INC.
Ticker Symbol	RVPH
CIK	0001742927
Industry	Pharmaceutical Preparations

Insider Information

Field	Value
Name	Patel Purav
CIK	0001818246
Title/Position	null
Relationship	Director

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-12-18
Transaction Code	A (Grant)
Security Type	Stock Option (right to buy)
Shares Involved	8,200
Price Per Share	$0.00
Total Value	$0
Shares Owned After	8,200 (Options)
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0
% of Market Cap	0.0%
Shares Transacted	8,200
% of Shares Outstanding	Not Available
Post-Transaction Ownership	8,200 options
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The transaction has a value of $0 and is immaterial against the company's $60 million market capitalization.
• Dilution Impact: As this is an option grant, it represents potential future dilution upon exercise. The exact impact cannot be calculated as the number of shares outstanding is not available. However, the number of shares is small and typical for a director grant.
• Transaction Significance: The transaction is a routine compensatory award to a director, as outlined in the company's 2020 Equity Incentive Plan. It carries low significance as it is not an open-market trade reflecting insider sentiment.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: This is a non-market, pre-planned compensatory grant with a $0 transaction value. It does not provide any new signal to the market.

Volume & Sentiment

• Expected Volume Impact: None. This was not an open-market transaction.
• Sentiment Indicator: Neutral. The filing is a routine disclosure of director compensation.

Additional Context

Transaction Notes

• Vesting Schedule: The options vest 100% on the one-year anniversary of the grant date (December 18, 2026), contingent on the reporting person remaining a director.
• Exercise Price: The option has an exercise price of $0.5848 per share.